Date: 2015-09-07
Type of information: Granting of a patent
Product name: CAP®GT platform
Compound: expression platform
Therapeutic area: Technology - Services
Action mechanism: The CAP®GT expression platform provides a fully scalable, regulatory endorsed production system for gene therapy vectors. CAP®GT cells grow to high cell densities and show a broad viral propagation spectrum including lentivirus, adenovirus and adeno-associated virus.
Company: CEVEC Pharmaceuticals (Germany)
Disease:
Latest news: * On September 7, 2015, CEVEC Pharmaceuticals, the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, announced the introduction of its cell-expression system, CAP®GT for the fully scalable production of gene therapy vectors, based on the Company’s proprietary CAP® technology. With CAP®GT cell lines, CEVEC provides a novel platform for the industrial production of viral vectors for gene therapy applications. CAP®GT cells propagate a broad spectrum of viral species supporting lentiviral, adenoviral and adeno-associated viral vectors. Growing in serum-free suspension culture, the CAP®GT expression system provides high cell densities, reduces production costs, and allows for safer and more efficient scale-up when compared to adherent cell culture systems. As demonstrated in adenoviral vector production runs, the CAP®GT platform offers the significant advantage over HEK293 cells, that no replication competent adenovirus (RCA) can be detected in the vector preparation. Independent study results indicate that CAP®GT derived lentiviral vector production results in vector titers comparable to or even exceeding production with HEK293 cells. Given the easy scale up of the CAP®GT suspension cell lines, industrial scale production is feasible. CEVEC’s CAP®GT technology meets necessary regulatory requirements. Derived from a non-tumor human origin, the cell line was developed according to industrial standards with complete documentation and full certification of materials. A master file is currently in process to be submitted for approval to the FDA.
Patents:
Submission of marketing authorization application USA :
Submission of marketing authorization application UE:
Withdrawal of marketing authorization application USA:
Withdrawal of marketing authorization application UE:
US authorization:
UE authorization:
Favourable opinion UE:
Favourable opinion USA:
Orphan status USA:
Orphan status UE:
Pediatric exclusivit _USA:
Pediatric exclusivity UE: OTC status: Other news: